SuperGen, Astex Management Sell Merger Strategy To Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
After announcing a merger of the biotechs, management sought to convince investors the combination offers the best long-term value for both sides during an analyst day.
You may also be interested in...
SuperGen Buys U.K.'s Astex, Building Cash-Rich Oncology Play
The deal brings private Astex a long-sought NASDAQ listing and beefs up cash-rich SuperGen's lackluster pipeline.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.